DOXAZOSIN AND CAPTOPRIL IN MILDLY HYPERCHOLESTEROLEMIC HYPERTENSIVE PATIENTS - THE DOXAZOSIN-CAPTOPRIL IN HYPERCHOLESTEROLEMIC HYPERTENSIVES STUDY

The evidence linking hypertension and hypercholesterolemia is strong and has fueled research into possible adverse effects of some antihypertensive agents on serum lipid profile. This multicenter, open, parallel study compares the effects of doxazosin and captopril on blood pressure, serum lipid levels, and quality of life in 224 hypercholesterolemic hypertensive patients. Blood pressure was significantly reduced in both treatment groups (p<0.001) and was normalized (standing diastolic pressure less-than-or-equal-to 90 mm Hg) in 73% of the doxazosin patients and 67% of the captopril group. Serum total cholesterol level was favorably reduced by both doxazosin (from 238 to 223 mg/dl, p<0.001) and captopril (from 245 to 233 mg/dl, p<0.001), whereas high density lipoprotein cholesterol concentration increased only in the doxazosin group (from 33 to 36 mg/dl,p<0.001). The calculated 10-year risk for the development of coronary heart disease was reduced significantly (p<0.001) by 28% in the doxazosin group and by 19% in the captopril group. The quality or life evaluation showed beneficial changes in both treatment groups. As a result of proven antihypertensive efficacy and a lack of unfavorable effects on lipid parameters and health status measures, these findings support the use of both doxazosin and captopril as agents of first choice in the treatment of hypertensive patients with associated lipid abnormalities.